FinnGen Consortium Advances with €52M Funding - A New Phase in Genomic Research Unveiled

The esteemed FinnGen research consortium progresses into its next significant phase backed by €52 million of new investment. Since its inception in 2017, FinnGen has evolved into a global leader in biobank-based genomic research, developing a research resource integrating genomic information from 500,000 Finnish biobank participants with extensive health registry data. This new phase, supported by a coalition of academic partners, international pharmaceutical firms, and public funding, aims to deepen the understanding of disease mechanisms and progression, which is crucial for developing innovative drug therapies and improving personalized healthcare.